Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?

Current Colorectal Cancer Reports

Volumn 10, Issue 4, 2014, Pages 363-371

  Herbert, Katie ^a   Kerr, Rachel ^a   Kerr, David J ^a,b   Church, David N ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adjuvant therapy; Aspirin; Colorectal cancer; COX 2; HLA 1; NSAIDs; PIK3CA

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; BETA CATENIN; BIOLOGICAL MARKER; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GROWTH DIFFERENTIATION FACTOR 15; HLA A1 ANTIGEN; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN; PROTEIN PIK3CA; ROFECOXIB; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER REGISTRY; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; METASTASIS; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 85027949789     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-014-0247-0     Document Type: Review

References (72)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
2. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.
3. Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9.
4. Ali R, Toh HC, Chia WK. The utility of aspirin in dukes C and high risk dukes B colorectal cancer—the ASCOLT study: study protocol for a randomized controlled trial. Trials. 2011;12:261. Trial protocol for ongoing multicentre randomised controlled trial of low-dose (200 mg) aspirin vs. placebo in adjuvant treatment of CRC.
5. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.
6. Twelves C, Wong A, Nowacki MP, Abt M, Burris 3rd H, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–704.
7. Park JH, McMillan DC, Horgan PG, Roxburgh CS. The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. Cancer Treat Rev. 2014;40(1):68–77.
8. Crawford S. Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence. Ther Adv Med Oncol. 2014;6(2):52–68.
9. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518–27. Systematic summary of data regarding aspirin effect on CRC outcomes from randomised and observational studies.
10. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891–9.
11. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7.
12. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5(2):164–78.
13. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603–13.
14. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12.
15. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–50.
16. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–601.
17. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MKB, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105(8):1107–13.
18. Schrör K. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol. 2011;25(4):473–84.
19. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.
20. Greenspan EJ, Madigan JP, Boardman LA, Rosenberg DW. Ibuprofen inhibits activation of nuclear β-catenin in human colon adenomas and induces the phosphorylation of GSK-3β. Cancer Prev Res. 2011;4(1):161–71.
21. Gao F, Liao C, Liu L, Tan A, Cao Y, Mo Z. The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. Color Dis. 2009;11(9):893–901.
22. Boon EMJ, Keller JJ, Wormhoudt TAM, Giardiello FM, Offerhaus GJA, van der Neut R, et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004;90(1):224–9.
23. Burn J, Bishop DT, Mecklin JP, Macrae F, Moslein G, Olschwang S, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359(24):2567–78.
24. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328(18):1313–6.
25. Neugut AI. Aspirin as adjuvant therapy for stage III colon cancer: standard of care? JAMA Intern Med. 2014;174(5):739–41.
26. Baron JA. Aspirin and cancer: trials and observational studies. J Natl Cancer Inst. 2012;104(16):1199–200.
27. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106(9):1564–70.
28. Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, et al. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. Gastroenterology. 2014;146(3):700–708.e2.
29. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649–58.
30. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer—reinterpreting paradigms. Nat Rev Clin Oncol. 2012;9(10):561–70.
31. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut. 2011;60(4):491–8.
32. Fuchs CS, Meyerhardt JA, Heseltine DL, Niedzwiecki D, Hollis D, Chan AT, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803. J Clin Oncol (Meeting Abstracts). 2005;23(16):Suppl 3530.
33. Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y. Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer. 2013;109(7):1921–5.
34. McCowan C, Munro AJ, Donnan PT, Steele RJ. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer. 2013;49(5):1049–57.
35. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010;59(12):1670–9.
36. Reimers MS, Bastiaannet E, van Herk-Sukel MP, Lemmens VE, van den Broek CB, van de Velde CJ, et al. Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. J Am Geriatr Soc. 2012;60(12):2232–6.
37. Walker AJ, Grainge MJ, Card TR. Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer. 2012;107(9):1602–7.
38. Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, et al. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer. 2009;115(24):5662–71.
39. Langley RE, Rothwell PM. Aspirin in gastrointestinal oncology: new data on an old friend. Curr Opin Oncol. 2014;26(4):441–7. Summary of evidence leading to the Add-Aspirin trial with description of trial protocol of aspirin at 100 or 300 mg vs. placebo in adjuvant treatment of CRC.
40. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014;33:2949–55.
41. Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.
42. Langley RE, Rothwell PM. Biological markers: potential biomarker for aspirin use in colorectal cancer therapy. Nat Rev Clin Oncol. 2013;10(1):8–10.
43. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–606. Observational data demonstrating reduction in cancer-specific death associated with low-dose aspirin use post diagnosis, restricted to those participants with PIK3CA mutation.
44. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309(24):2563–71.
45. Pendlebury S, Duchesne F, Reed KA, Smith JL, Kerr DJ. A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer. 2003;3(1):58–60.
46. Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31(34):4297–305. Molecular analysis of cohort of patients from the VICTOR trial demonstrating correlation between PIK3CA mutation and improved survival with aspirin use after CRC diagnosis.
47. Tuynman JB, Peppelenbosch MP, Richel DJ. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol/Hematol. 2004;52(2):81–101.
48. Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98(11):736–47.
49. Bruno A, Dovizio M, Tacconelli S, Patrignani P. Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2012;26(4):e1–e13.
50. Krishnan K, Ruffin MT, Normolle D, Shureiqi I, Burney K, Bailey J, et al. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001;10(5):447–53.
51. Sample D, Wargovich M, Fischer SM, Inamdar N, Schwartz P, Wang X, et al. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 2002;11(3):275–9.
52. Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med. 2014;174(5):732–9. Observational study demonstrating improved survival in participants using aspirin post-diagnosis with HLA class 1 antigen expression vs those missing HLA-1 expression. Does not show greater benefit of aspirin with PIK3CA mutation demonstrated by Domingo et al. and Liao et al.
53. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353(9149):307–14.
54. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med. 2007;357(4):360–9.
55. Sheehan KM, Sheahan K, O’Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999;282(13):1254–7.
56. Al-Maghrabi J, Buhmeida A, Emam E, Syrjanen K, Sibiany A, Al-Qahtani M, et al. Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma. World J Gastroenterol. 2012;18(15):1793–9.
57. Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol. 2010;28(30):4575–80.
58. Auman JT, Church R, Lee S-Y, Watson MA, Fleshman JW, McLeod HL. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer. 2008;44(12):1754–60.
59. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131–42.
60. Almhanna K, El-Rayes B, Sethi S, Dyson G, Heilbrun L, Philip PA, et al. Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. Anticancer Res. 2012;32(8):3559–63.
61. National Cancer Institute: Oxaliplatin, leucovorin calcium, and fluorouracil with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery. NCT01150045. http://clinicaltrials.gov/ct2/show/record/NCT01150045; 2013.
62. Fuchs CS, Ogino S. Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex! J Clin Oncol. 2013;31(34):4358–61.
63. Cathomas G. PIK3CA in colorectal cancer. Front Oncol. 2014;4:35.
64. Farina Sarasqueta A, Zeestraten EC, van Wezel T, van Lijnschoten G, van Eijk R, Dekker JW, et al. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol (Dordr). 2011;34(6):523–31.
65. Placke T, Orgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–8.
66. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90.
67. Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med. 2014;6(233):233re2.
68. Mehta RS, Song M, Bezawada N, Wu K, Garcia-Albeniz X, Morikawa T, et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst. 2014;106(4):dju016.
69. Nan H, Morikawa T, Suuriniemi M, Imamura Y, Werner L, Kuchiba A, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105(24):1852–61.
70. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A. 2009;106(23):9409–13.
71. Evidence for the use of aspirin as a treatment for cancer and the planned Add-Aspirin trial. http://www.comtecmed.com/cigi/2013/Abstracts_Text.aspx.
72. Ye X, Fu J, Yang Y, Chen S. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS One. 2013;8(2):e57578.